Table 4 |
||||
|
Baseline predictive factors of radiographic outcome at 10 years (univariate analysis) |
||||
| Baseline variables |
Total Sharp score at 10 years |
Radiographic progression |
||
|
|
||||
| p |
OR (95% CI) |
p |
OR (95% CI) |
|
|
|
||||
| Total Sharp score |
< 0.0001 |
8.66 (3.72–20.15) |
0.003 |
3.72 (1.51–9.15) |
| Erosion score |
< 0.0001 |
6.00 (2.68–13.39) |
< 0.0001 |
8.47 (2.98–24.05) |
| Joint narrowing score |
< 0.0001 |
4.71 (2.14–10.34) |
0.007 |
3.18 (1.33–7.62) |
| ACPA |
0.002 |
3.91 (1.59–9.61) |
< 0.0001 |
10.88 (4.03–29.3) |
| Anti-CCP antibodies |
0.005 |
3.37 (1.40–8.11) |
< 0.0001 |
8.62 (2.97–25.00) |
| IgA RF positivity |
0.01 |
3.19 (1.28–7.91) |
0.0001 |
5.89 (2.27–15.28) |
| ESR |
0.01 |
2.55 (1.21–5.39) |
0.34 |
1.47 (0.66–3.26) |
| IgA RF level |
0.02 |
2.40 (1.10–5.21) |
0.004 |
3.86 (1.46–10.17) |
| MMP3 level |
0.03 |
2.60 (1.07–6.30) |
0.003 |
5.00 (1.61–15.50) |
| Anti-perinuclear antibodies |
0.03 |
2.28 (1.05–4.93) |
0.0002 |
6.11 (2.22–16.77) |
| Swollen joint count |
0.05 |
0.48 (0.23–1.00) |
0.88 |
1.05 (0.47–2.33) |
| Morning stiffness |
0.08 |
2.10 (0.90–4.87) |
0.31 |
1.65 (0.61–4.42) |
| HLA-DRB1*01 |
0.08 |
0.49 (0.22–1.10) |
0.07 |
0.47 (0.20–1.08) |
| Tender joint count |
0.08 |
0.48 (0.21–1.10) |
0.13 |
0.48 (0.18–1.26) |
| IgM RF positivity |
0.10 |
1.95 (0.87–4.39) |
0.001 |
4.08 (1.63–10.20) |
| CRP |
0.19 |
1.63 (0.77–3.42) |
0.49 |
1.32 (0.58–2.99) |
| DAS |
0.26 |
1.52 (0.73–3.16) |
0.44 |
1.36 (0.61–3.05) |
| Anti-keratin antibodies |
0.32 |
1.46 (0.68–3.12) |
0.02 |
2.76 (1.09–7.00) |
| Age |
0.34 |
1.42 (0.67–3.00) |
0.007 |
3.28 (1.35–7.98) |
| Sex |
0.40 |
0.67 (0.27–1.69) |
0.14 |
0.42 (0.13–1.36) |
| Pain on VAS |
0.45 |
1.36 (0.60–3.07) |
0.44 |
0.69 (0.27–1.77) |
| YKL 40 |
0.56 |
1.69 (0.27–10.59) |
0.36 |
2.30 (0.36–14.66) |
| Anti-nuclear antibodies |
0.64 |
0.81 (0.34–1.93) |
0.79 |
1.13 (0.42–3.01) |
| Extra-articular signs |
0.68 |
1.29 (0.37–4.50) |
0.84 |
1.15 (0.28–4.63) |
| IgM RF level |
0.76 |
1.12 (0.52–2.39) |
0.01 |
3.05 (1.19–7.79) |
| Ritchie score |
0.85 |
1.06 (0.51–2.21) |
0.86 |
1.07 (0.48–2.38) |
| Anti-HSP90 antibodies |
0.92 |
0.95 (0.37–2.43) |
0.21 |
0.53 (0.19–1.44) |
| HAQ score |
0.95 |
0.97 (0.43–2.19) |
0.60 |
0.77 (0.30–2.00) |
|
|
||||
|
ACPA, anti-citrullinated protein antibody; CCP, cyclic citrullinated peptide; CI, confidence interval; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; HLA, human leucocyte antigen; HSP90, heat shock protein 90; MMP3, matrix metalloproteinase 3; OR, odds ratio; RF, rheumatoid factor; VAS, visual analogue score. |
||||
|
Courvoisier et al. Arthritis Research & Therapy 2008 10:R106 doi:10.1186/ar2498 |
||||
